|
|
Blood, 15 May 2007, Vol. 109, No. 10, pp. 4586-4588.
Prepublished online as a Blood First Edition Paper on January 18, 2007; DOI 10.1182/blood-2006-10-054924.
 Previous Article | Next Article 
Submitted October 27, 2006
Accepted January 14, 2007
Prognostic impact of elevated pre-transplant serum ferritin in patients undergoing myeloablative stem cell transplantation
Philippe Armand*, Haesook T Kim, Corey S Cutler, Vincent T Ho, John Koreth, Edwin P Alyea, Robert J Soiffer, and Joseph H Antin
Dept of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States
Dept of Biostatistics, Dana-Farber Cancer Institute, Boston, MA, United States
* Corresponding author; email: parmand{at}partners.org.
Iron overload could be a significant contributor to treatment-related mortality (TRM) for patients with hematologic malignancies undergoing hematopoietic stem cell transplantation (HSCT). We studied 590 patients who underwent myeloablative allogeneic HSCT at our institution, and on whom a pre-transplant serum ferritin was available. An elevated pre-transplant serum ferritin level was strongly associated with lower overall and disease-free survival. Subgroup multivariable analyses demonstrated that this association was restricted to patients with acute leukemia or myelodysplastic syndrome (MDS); in the latter group, the inferior survival was attributable to a significant increase in TRM. There was also a trend towards an increased risk of veno-occlusive disease in patients with high ferritin. Our results argue that iron overload plays an important role in transplantation outcome for patients with acute leukemia or MDS, as it does in thalassemia. They also suggest future prospective trials to examine the potential benefit of chelation therapy in this setting.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Articles in Blood Online:
-
Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem-cell transplantation
- Uwe Platzbecker, Gerhard Ehninger, and Martin Bornhäuser
Blood 2007 110: 3083.
[Full Text]
[PDF]
-
Response: Further analysis of the relationship between pretransplantation serum ferritin and transplantation outcome: cause-of-death analysis and impact of disease duration
- Philippe Armand
Blood 2007 110: 3083-3084.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
M. de Lima
SOS: too many irons in the fire!
Blood,
August 6, 2009;
114(6):
1137 - 1138.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. C. Maradei, A. Maiolino, A. M. de Azevedo, M. Colares, L. F. Bouzas, and M. Nucci
Serum ferritin as risk factor for sinusoidal obstruction syndrome of the liver in patients undergoing hematopoietic stem cell transplantation
Blood,
August 6, 2009;
114(6):
1270 - 1275.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M. Stone
How I treat patients with myelodysplastic syndromes
Blood,
June 18, 2009;
113(25):
6296 - 6303.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. P. Alessandrino, M. G. Della Porta, A. Bacigalupo, M. T. Van Lint, M. Falda, F. Onida, M. Bernardi, A. P. Iori, A. Rambaldi, R. Cerretti, et al.
WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO)
Blood,
August 1, 2008;
112(3):
895 - 902.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Cazzola, M. G. Della Porta, and L. Malcovati
Clinical Relevance of Anemia and Transfusion Iron Overload in Myelodysplastic Syndromes
Hematology,
January 1, 2008;
2008(1):
166 - 175.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. Platzbecker, G. Ehninger, and M. Bornhauser
Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem-cell transplantation
Blood,
October 15, 2007;
110(8):
3083 - 3083.
[Full Text]
[PDF]
|
|
|
|
|
